

Gender Transition in 2021-

A brief introduction

Vishal Patel, MD
Assistant Professor of Medicine,
Virginia Tech Carilion School of Medicine,
Carilion Clinic,
Roanoke, Virginia

Disclaimers – none

Resources

- Transhealth.ucsf.edu
- WPATH.org SOC VII
- Genderwellness.org
- Callen-Lorde
- PubMed
- NEJM



Objectives

- Understand “gender identity” and “gender transition”
- Barriers to access
- Hormone therapy in primary care clinic

Case

24 year old "Aaron" is here to discuss hormone therapy. Sex assigned at birth was male, always felt feminine. Currently lives by self. Patient says they prefer "Erin". Double major in Astrophysics and Biochemistry...

History of “Gender” in Medicine



The NEW ENGLAND
JOURNAL of MEDICINE

SUBSCRIBE
OR RENEW



PERSPECTIVE

Beyond the Rubble of Lake
Street — Minds in Crisis in a
City in Crisis

Covid-19 Vaccine
Resource Center

LEARN
MORE

CLINICAL PROBLEM-
SOLVING
Stalking the Diagnosis



EDITORIAL
Audio Interview: Delivering
Covid-19 Vaccines to Minority
Communities

PERSPECTIVE
“Vaccine Passport” Certification
— Policy and Ethical
Considerations



PERSPECTIVE
Emerging Infectious Diseases —
Learning from the Past and
Looking to the Future

PERSPECTIVE
From Vaccine Nati
Vaccine Equity —
Forward

MEDICINE AND SOCIETY

The Political Nature of Sex — Transgender in the History of Medicine

Ketil Slagstad, M.D.



Article

Metrics

34 References

ON JULY 18, 2016, THE FINAL RULE OF THE DEPARTMENT OF HEALTH AND HUMAN Services (HHS) implementing Section 1557 of the Affordable Care Act regarding gender nondiscrimination went into effect. Advocates were relieved that the law now included protections against discrimination in health care “on the basis of sex” that applied to transgender

March 18, 2021

N Engl J Med 2021; 384:1070-1074

DOI: 10.1056/NEJMms2029814

Editors

Debra Malina, Ph.D., Editor

400-300BC
Aristotle/Hippocrates
“Hermaphroditism”



19-20th century
Sex=Sexuality
“contrary sexual feeling”



Dr Harry Benjamin(1885-1986) – “Sex is what you see, gender is what you feel”.
Dr John Money (1921-2006)
– Gender identity/role imprinted/adapted in first 18 months



100-200 AD
Galen
Sexual ambiguity?



Magnus Hirschfeld – “the human being is not man or woman but man *and* woman.”



Early 20th century –
Birth of
psychoanalysis and
psychosexuality




“Gingerbread person”

The Genderbread Person v2.0

by its pronounced **METROsexual**.com


Gender is one of those things everyone thinks they understand, but most people don't. Like *Inception*. Gender isn't binary. It's not either/or. In many cases it's both/and. A bit of this, a dash of that. This tasty little guide is meant to be an appetizer for understanding. It's okay if you're hungry for more.



read more



bit.ly/ipmgbqr



Itspronouncedmetrosexual.com

Terminology/Definitions

- Cis gender (non-transgender) vs. Transgender
(not **transsexual**, **transvestite**) or Gender incongruent /
non confirming
- Gender binary Vs. Gender non-binary
- Male to female = Transgender Female
- Female to Male = Transgender Male
- Dysphoria – Strong sense of discomfort
- Ally/Activist

Better to ask preference or use neutral pronouns...


What causes gender dysphoria...

Levels of sexual identity

Level	Events	Timing
Chromosomal	XY=male	Fertilization
/genetic sex	XX=female	
Gonadal sex	Undifferentiated structures becomes testis or ovary	9-16 weeks post fertilization
Phenotypic sex	Internal and external reproductive structures	8 weeks post fertilization to puberty
Gender identity	Strong feelings of being male or female develop	childhood

Gender-Identity Formation

- Typical prenatal differentiation
 - 23 human chromosomes
 - 22 autosomes and 1 sex chromosome
- Chromosomal sex
 - XX: female XY: male
 - DSS gene on X
 - SRY gene on Y



Androgen insensitivity?
 Androgen receptor gene mutation?
 Prenatal DES?
 Environmental/chemical exposures?
 Adrenal hyperplasia?
 Klinefelter's syndrome?

Can "dysphoria" be proven?

- **Neuroimaging -**

- >Regional gray matter variation in male-to-female transsexualism (Neuroimage 2009)
- >The microstructure of white matter in male to female transsexuals before cross-sex hormonal treatment. A DTI study (Journal of Psychiatric Research Feb 2011)
- >White matter microstructure in female to male transsexuals before cross-sex hormonal treatment. A diffusion tensor imaging study (Journal of Psychiatric Research Feb 2011) FTM
- >Structural Connectivity Networks of Transgender People (Cereb Cortex 2015)

- **Hormone levels** — "10-20% may have out of normal levels"

Epidemiology

- 0.2-4% in various communities
- ~ 1.4 million in USA
- 2-4K in Roanoke Valley

Trans-survey Virginia 2015

- Unemployment - 15-24% were fired or not hired
- Poverty - 23%
- Education — 51% verbally harassed
(K-12) 12% physically attacked
15% drop out (vs ~ 5.5%)
- Homelessness — 9%/year
26% lifetime
- Restrooms — 50% avoid public restrooms
23% avoid food or liquids when in public
- Healthcare - 23% reported denial of routine care because they were transgender
20% did not see a doctor when they needed to

Most discriminated group...

- 26% unemployment
- 41% were homeless at some point
- 34% with household income less than 10K/yr. – (TG 15%, Blacks 9%, over all 4%)
- 20% with HIV (AA 2%, over all 0.6%)
- 20% get fired from PCP for coming out
- 28% put off seeing their PCP
- Highest risk of Homicide related to hate crime – AA Transgender female

Barriers to care

- Barriers for Providers
- Barriers of Patients

Barriers for Providers

- Care not "important", "it's a choice"
- Lack of training – most common
- Lack of institutional support
- “System inertia” – insurance, coverage, liability, resources
- “regret/De-trans”, legal issues
- Religious beliefs

Barriers for Patients


- Marginalization in early life
- Lack of education
- High risk of drug use, physical and sexual abuse, prostitution
- Lack of access to health care
- Poor social support
- Bathrooms

Risks from Medical community

- Gender dysphoria (not Gender identity disorder), self-mutilation
- “Coming out” vs. transitioning
- Patient confidentiality
- Delay in care/suboptimal care

Gender transition

- Changing gender role
- May or may not change physical appearance
- May or may not include hormone therapy or surgery



www.gendervarianceeducation.com

Case

45 yo "Marla" comes to see your for hormone replacement. "Martin" is a biological male, has lived as a female since 5 years. Now feels they need to go through transition so they can be identified as they feel.

1. How to determine readiness for hormone therapy?
2. What if they have regret later?

Indications for hormone therapy/surgery

- Dysphoria — physical, psychological, psychosocial
- Dysphoria — Persistent, insistent, consistent post puberty
- Diagnosis — “ Gender dysphoria in adult”

Examples of patient who did not meet criteria

- Gender non-conforming and did not want physical changes
- Displayed poor handling of therapy
- #detrans...

Overview of treatment

- Surgery – “mind over body”
 - Most effective in improving dysphoria
- Hormones/pharmacotherapy
 - Improves dysphoria
 - physical transition
- Gender confirming interventions
 - Improves dysphoria

Gender affirming outcomes - Benefits

- Chew, Denise et al. “Hormonal Treatment in Young People With Gender Dysphoria: A Systematic Review.” *Pediatrics* 2017
- Moravek, Molly B. “Gender-Affirming Hormone Therapy for Transgender Men.” *Clinical obstetrics and gynecology*
- Murad, Mohammad Hassan et al. “Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes.” *Clinical endocrinology* vol. 72,2 (2010)

Hormone Therapy

- Feminization =

- A. Estrogen + Antiandrogens

- + B. Progesterone

- OR C . Estrogen + Bicalutamide (Casodex)

- Masculinization = Testosterone

Feminizing hormone

Permanent

- Breast growth
- Softening of skin
- Thinning of body hair
- Fat redistribution

Temporary

- Feminizing effect
- Mood swings
- Decreased libido

Does not affect voice or facial features.

Estrogen

- Synthetic Estradiol
- Oral (\$), Injection (\$\$\$), Transdermal (\$\$\$\$)
- Hepatic metabolism with orals

Effects - Breast growth, feminizing effects, mood swings, skin changes, fat redistribution

Anti-Androgens

- Spironolactone(\$) – antagonizes Androgen receptor
- Cyproterone Acetate (NA)– Pure androgen receptor blocker
- Bicalutamide(\$\$\$\$) – Anti Androgen receptor
- GnRH agonists (\$\$\$\$\$\$) - puberty delaying

Masculinizing therapy

Permanent:

- Increased musculature and decreased body fat (semi-permanent)
- The development of facial and body hair
- Deepening of the voice
- Male-pattern baldness (in some individuals) (treatable)
- Clitoromegaly
- Growth spurt and closure of growth plates if given before the end of puberty
- Breast atrophy - possible shrinking and/or softening of breasts

Temporary:

- Increased libido
- Redistribution of body fat
- Cessation of ovulation and menstruation
- Further muscle development (especially upper body)
- Increased sweat and changes in body odor
- Prominence of veins and coarser skin
- Acne (especially in the first few years of therapy if patient converts T to DHT swiftly)
- **Alterations in blood lipids (cholesterol and triglycerides)**
- **Polycythemia**

Testosterone

- Injections (\$\$\$) - *****
- Patches/gel (\$\$\$\$)- ****
- Topical cream (\$) - **
- Implant (\$\$\$\$\$)- *****

DHEA/high dose testosterone – Gets aromatized to estrogen.

Side effects

	Estrogen	Testosterone
Likely increased risk	Venous thromboembolic disease Gallstone Elevated liver enzymes Weight gain Hypertriglyceridemia	Polycythemia Weight gain Acne Androgenic alopecia Sleep Apnea
Increased risk with additional risks factors	Cardiovascular disease	
Possible increased risk	Hypertension Diabetes Prolactinoma	Elevated Liver enzymes Hyperlipidemia
No increased risk or inconclusive	Breast Cancer	Osteoporosis Breast, cervical, ovarian, uterine cancer

Gender affirming outcomes- Safety

1. Wierckx, Katrien et al. "Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence." *The journal of sexual medicine* vol. 11,8 (2014): 1999-2011. doi:10.1111/jsm.12571
2. Abdala, Rubén et al. "Perfil de seguridad a corto plazo de la terapia hormonal cruzada en trans-varones" [Short-term safety profile of cross-hormonal therapy in trans-male subjects]. *Medicina* vol. 78,6 (2018): 399-402.
3. Connelly, Paul J et al. "Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults." *Hypertension (Dallas, Tex. : 1979)* vol. 74,6 (2019): 1266-1274. doi:10.1161/HYPERTENSIONAHA.119.13080

Mental illness

- Most frequent co-morbidity
- Higher rate of chemical dependence
- Continue Psychiatric care and counselling
- May have decreased need in with HRT/transition

Primary care issues

- Higher incidence and prevalence of STDs
- Higher rate of long term illnesses
- Decreased rate of cancer screening
- Low health literacy and access

How to be gender non-confirming inclusive practice

- Gender-neutral restrooms
- Rainbow flags/pictures/paintings
- Family pictures of same sex couples/transgender personalities etc.
- Third gender option on intake forms
- "SOGI" adaptation in EMR - "Sexual Orientation Gender Identity"

Insurance coverage

- Virginia Medicaid, major private insurance providers cover most of the services
- Gender reassignment not approved
- Some gender confirming procedures approved
- Cost – GRS (18-30K)
 - Mastectomy (4k-8k)
 - Injections ~\$250/3 months

Carilion Gender Care Clinic

- At Riverside 3 clinic since Oct 2016 (CGCR)
- 200+ patients from South-West VA
- ½ day per week
- No referral required

SOGI - EPIC

Sexual Orientation and Gender Identity SmartForm



Inform the patient that anything entered here will be visible to anyone with access to this legal medical record.

Sexuality

Patient's sexual orientation:

Legal Information

Legal first name:

Legal last name:

Legal sex:

Gender Identity

Autofill with default responses for:

Patient's gender identity:

Patient's sex assigned at birth:

Patient pronouns:

Affirmation steps patient has taken, if any: ☐

Patient's future affirmation plans, if any:

Organ Inventory

☐ Organs the patient currently has:

+ breasts	—
+ cervix	—
+ ovaries	—
+ uterus	—
+ vagina	—
+ penis	—
+ prostate	—
+ testes	—

☐ Organs present at birth or expected at birth to develop:

+ breasts	—
+ cervix	—
+ ovaries	—
+ uterus	—
+ vagina	—
+ penis	—
+ prostate	—
+ testes	—

☐ Organs surgically enhanced or constructed:

+ breasts	—
+ vagina	—
+ penis	—

☐ Organs hormonally enhanced or developed:

+ breasts	—
-----------	---

Summary

- Transgender patients are most underserved, underrepresented minority
- Persistent, consistent, insistent dysphoria after puberty= very low regret
- Side effects of hormone supplement
- Treatments for transition are effective, but far from “mainstream” medicine
- Resources are improving ...

Thank You!